SOCS2 negatively regulates growth hormone action in vitro and in vivo

Journal of Clinical Investigation

Volumn 115, Issue 2, 2005, Pages 397-406

  Greenhalgh, Christopher J ^a   Rico Bautista, Elizabeth ^b   Lorentzon, Mattias ^c   Thaus, Anne L ^d   Morgan, Phillip O ^a   Willson, Tracy A ^a   Zervoudakis, Panagiota ^d   Metcalf, Donald ^a   Street, Ian ^a   Nicola, Nicos A ^a   Nash, Andrew D ^d   Fabri, Louis J ^d   Norstedt, Gunnar ^b   Ohlsson, Claes ^c   Flores Morales, Amilcar ^b   Alexander, Warren S ^a   Hilton, Douglas J ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Zenyth Therapeutics Limited Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; GROWTH HORMONE RECEPTOR; REPRESSOR PROTEIN; SOCS2 PROTEIN, MOUSE; SOMATOMEDIN C; TRANSACTIVATOR PROTEIN; TYROSINE;

AMINO ACID ANALYSIS; ARTICLE; BIOCHEMISTRY; BODY HEIGHT; BODY SIZE; BODY WEIGHT; GENE MUTATION; GROWTH REGULATION; HORMONE ACTION; HORMONE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LEG LENGTH; NONHUMAN; ORGAN WEIGHT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; LIVER; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AMINO ACID MOTIFS; ANIMALS; BODY WEIGHT; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; LIVER; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, SOMATOTROPIN; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANS-ACTIVATORS; TYROSINE;

EID: 20144380439     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200522710     Document Type: Article

References (55)

1. Press, M. 1988. Growth hormone and metabolism. Diabetes Metab. Rev. 4:391-414.
2. Sonksen, P.H., Salomon, F., and Cuneo, R. 1991. Metabolic effects of hypopituitarism and acromegaly. Horm. Res. 36:S27-S31.
3. [Anonymous]. 1998. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the growth hormone research society workshop on adult growth hormone deficiency. J. Clin. Endocrinol. Metab. 83:379-381.
4. Monson, J.P. 2003. Long-term experience with GH replacement therapy: efficacy and safety. Eur. J. Endocrinol. 148:S9-S14.
5. Bramnert, M., et al. 2003. Growth hormone replacement therapy induces resistance by activating the glucose-fatty acid cycle. J. Clin. Endocrinol. Metab. 88:1455-1463.
6. Hanada, T., Kinjyo, I., Inagaki-Ohara, K., and Yoshimura, A. 2003. Negative regulation of cytokine signaling by CIS/SOCS family proteins and their roles in inflammatory diseases. Rev. Physiol. Biochem. Pharmacol. 149:72-86.
7. Alexander, W.S. 2002. Suppressors of cytokine signalling (SOCS) in the immune system. Nat. Rev. Immunol. 2:410-416.
8. Alexander, W.S., et al. 1999. SOCS1 is a critical inhibitor of interferon gamma signaling and prevents the potentially fatal neonatal actions of this cytokine. Cell. 98:597-608.
9. Lindeman, G.J., et al. 2001. SOCS1 deficiency results in accelerated mammary gland development and rescues lactation in prolactin receptor-deficient mice. Genes Dev. 15:1631-1636.
10. Chong, M.M., et al. 2003. Suppressor of cytokine signaling-1 is a critical regulator of interleukin-7-dependent CD8+ T cell differentiation. Immunity. 18:475-487.
11. Roberts, A.W., et al. 2001. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc. Natl. Acad. Sci. U. S. A. 98:9324-9329.
12. Lang, R., et al. 2003. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4:546-550.
13. Takahashi, Y., et al. 2003. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J. 22:372-384.
14. Croker, B.A., et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4:540-545.
15. Yasukawa, H., et al. 2003. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4:551-556.
16. Croker, B.A., et al. 2004. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity. 20:153-165.
17. Metcalf, D., et al. 2000. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature. 405:1069-1073.
18. Palmiter, R.D., et al. 1982. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature. 300:611-615.
19. Mathews, L.S., et al. 1988. Growth enhancement of transgenic mice expressing human insulin-like growth factor 1. Endocrinology. 123:2827-2833.
20. Horvat, S., and Medrano, J.F. 2001. Lack of Socs2 expression causes the high-growth phenotype in mice. Genomics. 72:209-212.
21. Hansen, J.A., Lindberg, K., Hilton, D.J., Nielsen, J.H., and Billestrup, N. 1999. Mechanism of inhibition of growth hormone receptor signaling by suppressor of cytokine signaling proteins. Mol. Endocrinol. 13:1832-1843.
22. Ram, P.A., and Waxman, D.J. 1999. SOCS/C1S protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274:35553-35561.
23. Dey, B.R., Spence, S.L., Nissley, P., and Furlanetto, R.W. 1998. Interaction of human suppressor of cytokine signaling (SOCS)-2 with the insulin-like growth factor-I receptor. J. Biol. Chem. 273:24095-24101.
24. Lopaczynski, W. 1999. Differential regulation of signaling pathways for insulin and insulin-like growth factor 1. Acta Biochim. Pol. 46:51-60.
25. Udy, G.B., et al. 1997. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. U. S. A. 94:7239-7244.
26. Teglund, S., et al. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:841-850.
27. Greenhalgh, C.J., et al. 2002. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol. Endocrinol. 16:1394-1406.
28. Greenhalgh, C.J., et al. 2002. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J. Biol. Chem. 277:40181-40184.
29. Wajnrajch, M.P., Gertner, J.M., Harbison, M.D., Chua, S.C., Jr., and Leibel, R.L. 1996. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat. Genet. 12:88-90.
30. Beamer, W.H., and Eicher, E.M. 1976. Stimulation of growth in the little mouse. J. Endocrinol. 71:37-45.
31. Flores-Morales, A., et al. 2001. Endoplasmic reticulum stress prolongs GH-induced Janus kinase (JAK2)/signal transducer and activator of transcription (STAT5) signaling pathway. Mol. Endocrinol. 15:1471-1483.
32. Tollet-Egnell, P., et al. 2001. Gene expression profile of the aging process in rat liver: normalizing effects of growth hormone replacement. Mol. Endocrinol. 15:308-318.
33. Hilton, D.J., et al. 1998. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc. Natl. Acad. Sci. U. S. A. 95:114-119.
34. Kile, B.T., et al. 2002. The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 27:235-241.
35. Favre, H., Benhamou, A., Finidori, J., Kelly, P.A., and Edery, M. 1999. Dual effects of suppressor of cytokine signaling (SOCS-2) on growth hormone signal transduction. FEBS Lett. 453:63-66.
36. Adams, T.E., et al. 1998. Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling. J. Biol. Chem. 273:1285-1287.
37. Kamura, T., et al. 1998. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12:3872-3881.
38. Zhang, J.G., et al. 1999. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U. S. A. 96:2071-2076.
39. Stofega, M.R., Herrington, J., Billestrup, N., and Carter-Su, C. 2000. Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol. Endocrinol. 14:1338-1350.
40. Ullman, E.F., et al. 1994. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc. Natl. Acad. Sci. U. S. A. 91:5426-5430.
41. Ullman, E.F., et al. 1996. Luminescent oxygen channeling assay (LOC1): sensitive, broadly applicable homogeneous immunoassay method. Clin. Chem. 42:1518-1526.
42. Yakar, S., et al. 2002. Circulating levels of IGF-1 directly regulate bone growth and density. J. Clin. Invest. 110:771-781. doi:10.1172/JCI200215463.
43. Nicholson, S.E., et al. 1999. Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J. 18:375-385.
44. Zhang, J.G., et al. 2001. The SOCS box of suppressor of cytokine signaling-1 is important for inhibition of cytokine action in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:13261-13265.
45. Yasukawa, H., et al. 1999. The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18:1309-1320.
46. Kim, S.O., Jiang, J., Yi, W., Feng, G.S., and Frank, S.J. 1998. Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling. J. Biol. Chem. 273:2344-2354.
47. Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P.C., and Schaper, F. 2000. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275:12848-12856.
48. Nicholson, S.E., et al. 2000. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. U. S. A. 97:6493-6498.
49. Fairlie, W.D., De Souza, D., Nicola, N.A., and Baca, M. 2003. Negative regulation of gp130 signalling mediated through tyrosine-757 is not dependent on the recruitment of SHP2. Biochem. J. 372:495-502.
50. Gu, F., et al. 2003. Protein tyrosine phosphatase 1B attenuates growth hormone-mediated JAK2-STAT signaling. Mol. Cell Biol. 23:3753-3762.
51. Godfrey, P., et al. 1993. GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat. Genet. 4:227-232.
52. -/- mice. J. Clin. Invest. 104:895-901.
53. Hansen, L.H., et al. 1996. Identification of tyrosine residues in the intracellular domain of the growth hormone receptor required for transcriptional signaling and Stat5 activation. J. Biol. Chem. 271:12669-12673.
54. Pang, S.T., et al. 2002. Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology. 143:4897-4906.
55. Tusher, V.G., Tibshirani, R., and Chu, G. 2001. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98:5116-5121.